Marker Therapeutics, Inc.

NasdaqCM:MRKR Stok Raporu

Piyasa değeri: US$32.7m

Marker Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Marker Therapeutics's earnings are forecast to decline at 33.3% per annum while its annual revenue is expected to grow at 81% per year. EPS is expected to grow by 4.3% per annum.

Anahtar bilgiler

-33.3%

Kazanç büyüme oranı

4.3%

EPS büyüme oranı

Biotechs kazanç büyümesi27.1%
Gelir büyüme oranı81.0%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme21 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17
Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22
Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Marker shares rise as it completes construction of its cGMP manufacturing facility

Jan 13

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Jan 05

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29
Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Marker Therapeutics EPS misses by $0.02

Nov 09

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:MRKR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2026N/A-44N/AN/A1
12/31/2025N/A-35N/AN/A1
12/31/20244-15N/AN/A1
6/30/20244-10-11-11N/A
3/31/20243-12-14-14N/A
12/31/20233-14-16-16N/A
9/30/20233-14-20-20N/A
6/30/20234-17-27-27N/A
3/31/20234-14-18-21N/A
12/31/20224-20-27-27N/A
9/30/20224-26-26-26N/A
6/30/20223-33-27-25N/A
3/31/20222-43-36-31N/A
12/31/20211-42-30-27N/A
9/30/2021N/A-41-35-28N/A
6/30/2021N/A-36-34-27N/A
3/31/20210-31-35-24N/A
12/31/20200-29-29-20N/A
9/30/20201-25-24-19N/A
6/30/20201-23-23-19N/A
3/31/20200-23-19-19N/A
12/31/20190-21-19-18N/A
9/30/2019N/A-152-20-20N/A
6/30/2019N/A-151-18-18N/A
3/31/20190-150-16-16N/A
12/31/20180-148-15-14N/A
9/30/20180-15-11-11N/A
6/30/20180-15-9-9N/A
3/31/20180-12N/A-9N/A
12/31/20170-11N/A-8N/A
9/30/20170-10N/A-8N/A
6/30/2017N/A-8N/A-8N/A
3/31/2017N/A0N/A-8N/A
12/31/2016N/A-2N/A-7N/A
9/30/2016N/A-3N/A-6N/A
6/30/2016N/A28N/A-5N/A
3/31/2016N/A-38N/A-4N/A
12/31/2015N/A-34N/A-4N/A
9/30/2015N/A-33N/A-4N/A
6/30/2015N/A-63N/A-3N/A
3/31/2015N/A-2N/A-3N/A
12/31/2014N/A-31N/A-2N/A
9/30/2014N/A-34N/A-1N/A
6/30/2014N/A-33N/A-1N/A
3/31/2014N/A-35N/A-1N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MRKR is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: MRKR is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: MRKR is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: MRKR's revenue (81% per year) is forecast to grow faster than the US market (8.9% per year).

Yüksek Büyüme Geliri: MRKR's revenue (81% per year) is forecast to grow faster than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if MRKR's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin